Sunshine Biopharma, Inc. (SBFM)
USD 2.75
(0.37%)
USD 2.75
(0.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.12 Million USD | 25.12% |
| 2022 | 10.37 Million USD | 306.57% |
| 2021 | 2.55 Million USD | 309.8% |
| 2020 | 622.43 Thousand USD | -4.49% |
| 2019 | 651.7 Thousand USD | -46.7% |
| 2018 | 1.22 Million USD | 42.64% |
| 2017 | 857.19 Thousand USD | -13.69% |
| 2016 | 993.1 Thousand USD | 27.0% |
| 2015 | 781.98 Thousand USD | -55.45% |
| 2014 | 1.75 Million USD | -9.35% |
| 2013 | 1.93 Million USD | 173.97% |
| 2012 | 706.68 Thousand USD | 27.05% |
| 2011 | 556.2 Thousand USD | 3.5% |
| 2010 | 537.38 Thousand USD | 2686810.0% |
| 2009 | 20.00 USD | -99.92% |
| 2008 | 26.07 Thousand USD | 98.74% |
| 2007 | 13.12 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.57 Million USD | -2.42% |
| 2024 Q1 | 3.66 Million USD | 6.99% |
| 2023 Q3 | 2.76 Million USD | -5.87% |
| 2023 Q1 | 3.65 Million USD | -43.98% |
| 2023 Q2 | 2.94 Million USD | -19.54% |
| 2023 Q4 | 3.42 Million USD | 23.59% |
| 2023 FY | 12.97 Million USD | 25.12% |
| 2022 Q4 | 6.52 Million USD | 265.71% |
| 2022 Q2 | 771.42 Thousand USD | -40.02% |
| 2022 FY | 10.37 Million USD | 306.57% |
| 2022 Q1 | 1.28 Million USD | 323.83% |
| 2022 Q3 | 1.78 Million USD | 131.39% |
| 2021 Q3 | 527.12 Thousand USD | 24.63% |
| 2021 Q1 | 1.29 Million USD | 259.46% |
| 2021 Q4 | 303.46 Thousand USD | -42.43% |
| 2021 Q2 | 422.95 Thousand USD | -67.39% |
| 2021 FY | 2.55 Million USD | 309.8% |
| 2020 FY | 622.43 Thousand USD | -4.49% |
| 2020 Q4 | 360.86 Thousand USD | 362.07% |
| 2020 Q2 | 138.55 Thousand USD | 208.46% |
| 2020 Q3 | 78.09 Thousand USD | -43.63% |
| 2020 Q1 | 44.91 Thousand USD | -82.52% |
| 2019 FY | 651.7 Thousand USD | -46.7% |
| 2019 Q1 | 155.66 Thousand USD | -4.86% |
| 2019 Q2 | 67.77 Thousand USD | -56.46% |
| 2019 Q3 | 204.67 Thousand USD | 202.01% |
| 2019 Q4 | 256.96 Thousand USD | 25.55% |
| 2018 FY | 1.22 Million USD | 42.64% |
| 2018 Q4 | 163.61 Thousand USD | -47.88% |
| 2018 Q3 | 313.89 Thousand USD | -46.49% |
| 2018 Q2 | 586.57 Thousand USD | 127.47% |
| 2018 Q1 | 257.86 Thousand USD | 59.0% |
| 2017 Q4 | 162.17 Thousand USD | 42.5% |
| 2017 Q3 | 113.8 Thousand USD | -75.9% |
| 2017 Q2 | 472.21 Thousand USD | 333.27% |
| 2017 Q1 | 108.99 Thousand USD | -67.57% |
| 2017 FY | 857.19 Thousand USD | -13.69% |
| 2016 Q4 | 336.09 Thousand USD | 189.7% |
| 2016 FY | 993.1 Thousand USD | 27.0% |
| 2016 Q3 | 116.01 Thousand USD | -75.38% |
| 2016 Q2 | 471.31 Thousand USD | 576.38% |
| 2016 Q1 | 69.68 Thousand USD | -60.01% |
| 2015 Q2 | 369.86 Thousand USD | 196.31% |
| 2015 Q3 | 113.05 Thousand USD | -69.43% |
| 2015 Q4 | 174.24 Thousand USD | 54.12% |
| 2015 FY | 781.98 Thousand USD | -55.45% |
| 2015 Q1 | 124.82 Thousand USD | -59.25% |
| 2014 Q3 | 277.42 Thousand USD | -63.76% |
| 2014 FY | 1.75 Million USD | -9.35% |
| 2014 Q2 | 765.51 Thousand USD | 88.61% |
| 2014 Q4 | 306.3 Thousand USD | 10.41% |
| 2014 Q1 | 405.87 Thousand USD | -40.78% |
| 2013 Q2 | 152.59 Thousand USD | -83.47% |
| 2013 Q1 | 922.89 Thousand USD | 390.23% |
| 2013 Q4 | 685.41 Thousand USD | 285.75% |
| 2013 FY | 1.93 Million USD | 173.97% |
| 2013 Q3 | 177.68 Thousand USD | 16.44% |
| 2012 Q3 | 376.4 Thousand USD | 266.54% |
| 2012 Q2 | 102.69 Thousand USD | 161.14% |
| 2012 Q4 | 188.25 Thousand USD | -49.99% |
| 2012 Q1 | 39.32 Thousand USD | -89.43% |
| 2012 FY | 706.68 Thousand USD | 27.05% |
| 2011 Q4 | 372.05 Thousand USD | 219.52% |
| 2011 Q3 | 116.44 Thousand USD | 606.13% |
| 2011 Q1 | 49.21 Thousand USD | -88.47% |
| 2011 FY | 556.2 Thousand USD | 3.5% |
| 2011 Q2 | 16.49 Thousand USD | -66.49% |
| 2010 Q2 | 1.58 Million USD | 4483.28% |
| 2010 Q4 | 426.94 Thousand USD | 128.23% |
| 2010 FY | 537.38 Thousand USD | 2686810.0% |
| 2010 Q3 | -1.51 Million USD | -195.23% |
| 2010 Q1 | 34.64 Thousand USD | 0.0% |
| 2009 FY | 20.00 USD | -99.92% |
| 2009 Q3 | 32 Thousand USD | 516.55% |
| 2009 Q2 | 5191.00 USD | 110.16% |
| 2009 Q1 | 2470.00 USD | -26.33% |
| 2008 Q3 | 4638.00 USD | 9.31% |
| 2008 Q4 | 3353.00 USD | -27.71% |
| 2008 FY | 26.07 Thousand USD | 98.74% |
| 2008 Q1 | 10.78 Thousand USD | 376.03% |
| 2008 Q2 | 4243.00 USD | -60.65% |
| 2007 Q4 | 2265.00 USD | -74.23% |
| 2007 FY | 13.12 Thousand USD | 0.0% |
| 2007 Q3 | 8788.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Theratechnologies Inc. | 72.75 Million USD | 81.961% |
| Harrow Health, Inc. | 89.97 Million USD | 85.413% |
| Dynavax Technologies Corporation | 219.14 Million USD | 94.011% |
| Biofrontera Inc. | 39.95 Million USD | 67.155% |
| Cronos Group Inc. | 96.7 Million USD | 86.429% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -38.942% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 94.346% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 66.479% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 237.271% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 69.507% |
| Radius Health, Inc. | 265.92 Million USD | 95.065% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 5.183% |
| DURECT Corporation | 43.71 Million USD | 69.977% |
| ProPhase Labs, Inc. | 37.85 Million USD | 65.327% |
| Safety Shot Inc | 12.1 Million USD | -8.38% |
| Phibro Animal Health Corporation | 260.29 Million USD | 94.958% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -327.62% |
| Alvotech | 285.43 Million USD | 95.402% |
| Assertio Holdings, Inc. | 368.58 Million USD | 96.439% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 97.519% |
| Rockwell Medical, Inc. | 15.37 Million USD | 14.632% |
| Procaps Group S.A. | 187.24 Million USD | 92.991% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 97.776% |
| SCYNEXIS, Inc. | 51.84 Million USD | 74.687% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 78.067% |
| Viatris Inc. | 5.96 Billion USD | 99.78% |
| OptiNose, Inc. | 85.1 Million USD | 84.578% |
| SIGA Technologies, Inc. | 22.04 Million USD | 40.46% |
| Tilray Brands, Inc. | 251.35 Million USD | 94.779% |
| PetIQ, Inc. | 192.72 Million USD | 93.19% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 0.0% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.178% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -34.875% |
| Alimera Sciences, Inc. | 62.64 Million USD | 79.048% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 91.756% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1621.26% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -122.994% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 95.822% |
| Journey Medical Corporation | 54.59 Million USD | 75.96% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 26.302% |
| Alpha Teknova, Inc. | 45.85 Million USD | 71.381% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 38.001% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 73.236% |
| PainReform Ltd. | 9.58 Million USD | -36.941% |
| Cosmos Health Inc. | 26.18 Million USD | 49.87% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 92.044% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -33.582% |
| Embecta Corp. | 528.4 Million USD | 97.516% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -228.84% |
| Talphera, Inc. | 11.99 Million USD | -9.425% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 95.979% |
| Incannex Healthcare Limited | 30.05 Million USD | 56.329% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 37.628% |
| Shineco, Inc. | 17.94 Million USD | 26.875% |
| Procaps Group, S.A. | 199.47 Million USD | 93.421% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 93.303% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 70.74% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 96.195% |
| Alvotech | 285.43 Million USD | 95.402% |
| Hempacco Co., Inc. | 7.59 Million USD | -72.771% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 90.673% |
| Bright Green Corporation | 8.25 Million USD | -59.029% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 95.173% |
| Kamada Ltd. | 45.42 Million USD | 71.108% |
| Indivior PLC | 911 Million USD | 98.559% |
| Evoke Pharma, Inc. | 12.4 Million USD | -5.76% |
| Flora Growth Corp. | 10.57 Million USD | -24.062% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 37.628% |
| Evolus, Inc. | 189.75 Million USD | 93.084% |
| HUTCHMED (China) Limited | 436.23 Million USD | 96.991% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 91.485% |
| Akanda Corp. | 3.48 Million USD | -276.76% |